The effects of lesions in the compact part of the substantia nigra on glutamate and GABA release in the pedunculopontine nucleus;Efecto de la lesión de la sustancia negra pars compacta sobre la liberación de glutamato y GABA en el núcleo pedunculopontino

Revista de Neurologia

Volumn 40, Issue 1, 2005, Pages 23-29

  Blanco Lezcano, Lisette ^a   Rocha Arrieta, L L ^b   Alvarez Gonzalez L ^a   Martinez Marti L ^a   Pavon Fuentes N ^a   Gonzalez Fraguela M E ^a   Bauza Calderin Y ^a   Coro Grave De Peralta, Y ^a  

^a CENTRO INTERNACIONAL DE RESTAURACIÓN NEUROLÓGICA CIREN   (Cuba)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

6 OHDA; Microdialysis technique; Parkinsonism; PPN; STN

Indexed keywords

4 AMINOBUTYRIC ACID; GLUTAMIC ACID; OXIDOPAMINE; POTASSIUM; QUINOLINIC ACID; ADRENERGIC RECEPTOR STIMULATING AGENT; DOPAMINE;

4 AMINOBUTYRIC ACID RELEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; BRAIN STEM; CEREBROSPINAL FLUID; CONTROLLED STUDY; DISEASE MODEL; DOPAMINERGIC NERVE CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MESENCEPHALON; MICRODIALYSIS; NERVE CELL DEGENERATION; NEUROTRANSMITTER RELEASE; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PEDUNCULOPONTINE NUCLEUS; RAT; RAT STRAIN; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; ZONA COMPACTA; ANIMAL; BRAIN; BRAIN LEVEL; CHEMISTRY; CYTOLOGY; DRUG EFFECT; HISTOLOGY; METABOLISM; NERVE CELL; PATHOLOGY; PEDUNCULOPONTINE TEGMENTAL NUCLEUS; WISTAR RAT;

ADRENERGIC AGENTS; ANIMALS; BRAIN; BRAIN CHEMISTRY; DOPAMINE; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; MALE; MICRODIALYSIS; NEURONS; OXIDOPAMINE; PARKINSON DISEASE; PEDUNCULOPONTINE TEGMENTAL NUCLEUS; RATS; RATS, WISTAR; SUBSTANTIA NIGRA;

EID: 24344446529     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4001.2004062     Document Type: Article

References (52)

1. Herrera-Marschitz M, Loidi FC, Zhi-Binh Y, Andreson K, Silveira R, O'Connor WT, et al. Neurocircuitry of the basal ganglia studied by monitoring neurotransmitter release. Mol Neurobiol 1994; 9: 171-82.
2. Scharwarting R, Bonatz AE, Carey RJ, Husoon JP. Relationship between indices of behavioral asymmetries and neurochemical changes following mesencephalic 6-OHDA injections. Brain Res 1991; 555: 46-55.
3. Sarre S, Michotte Y. HPLC with ED for the determination of levodopa; catecholamines and their metabolites in rat brain dialysates. J Chromat 1992; 575: 207-12.
4. Robertson G, Damsma G, Fibiger H. Characterization of dopamine release in the substantia nigra by in vivo microdialysis in freely moving rats. J Neurosci 1991; 11: 2209-16.
5. 1 mediated behavioral and electrophysiological effects. Synapse 1996; 23: 280-91.
6. Robinson TE, Mocsary Z, Camp D, Whishaw Q. Time course of recovery of extracellular dopamine following partial damage to the nigros-triatal dopamine system. J Neurosci 1994; 14: 2687-96.
7. Robinson T, Noordhorn M, Cham E, Mocsary Z, Camp D, Whishaw Q. Relationship between asymmetric in striatal dopamine release and the direction of amphetamine-induced rotation during the first week following a unilateral 6-OHDA lesion of the SN. Synapse 1994; 17: 16-25.
8. Sarre S, De Klippel N, Herregodts P, Ebinger G, Michotte Y. Biotransformation of locally applied L-DOPA in the corpus striatum of the hemiparkinsonian rat studied with microdialysis. Arch Pharmacol 1994; 350: 15-21.
9. Sarre S, Ebinger G, Michotte Y. Levodopa biotransformation in hemiparkinsonian rats: effects of dopamine receptor agonists and antagonists. Eur J Pharmacol 1996; 296: 247-60.
10. Morari M, Sbrenna S, Marti M, O'Connor WT, Bianchi C, Fuxe K, et al. Evidence for a striatal NMDA receptor modulation of nigral glutamate release. A dual probe microdialysis study in the awake freely moving rat. Eur J Neurosci 1998; 10: 1716-22.
11. Taguchi K, Atobe J, Kato M, Chuma T, Chikuma T, Shigenaga T, et al. The effect of methamphetamine on the release of acetylcholine in the rat striatum. Eur J Neurosci 1998; 360: 131-7.
12. Reynolds NC, Lin W, Cameron CM, Roering DL. Extracellular perfusion of rat brain nuclei using microdialysis: a method for studying differential neurotransmitter release in response to neurotoxins. Brain Res Protocols 1999; 4: 124-31.
13. Marti M, Sbrenna S, Fuxe K, Bianchi C, Beani L, Morari M. Increased responsivity of glutamate release from the substantia nigra pars reticulata to striatal NMDA receptor blockade in a model of Parkinson's disease. A dual probe microdialysis study in hemiparkinsonian rats. Eur J Neurosci 2000; 12: 1848-50.
14. Ferger B, Teismann P, Mierau J. The dopamine agonists pramipexole scavenges hydroxil free radicals induced by striatal application of 6-OHDA in rats: an in vivo microdialysis study. Brain Res 2000; 883: 216-23.
15. Lee MS, Rinne JO, Marsden CD. The pedunculopontine nucleus: its role in the genesis of movement disorders. Yonsei Med J 2000; 41: 167-84.
16. Carlsoon JD, Pearlstein RD, Buchholz J, Iacono RP, Maeda G. Regional metabolic changes in the pedunculopontine nucleus of unilateral 6-hydroxydopamine Parkinson's model rats. Brain Res 1999; 828: 12-9.
17. Bolam JP, Francis CM, Henderson Z. Cholinergic inputs to dopaminergic neurons in the substantia nigra. A double inmunocytochemical study. Neuroscience 1991; 41: 483-94.
18. Rye B, Saper C. Pedunculopontine tegmental nucleus of the rat: cytoarchitecture; cytochemistry and some extrapyramidal connections of the mesopontine tegmentum. J Comp Neurol 1987; 259: 483-528.
19. Lavoie B, Parent A. PPN in the squirrel monkey: distribution of cholinergic and monoaminergic neurons in the mesopontine tegmentum with evidence for the presence of GLU and cholinergic neurons. J Comp Neurol 1994; 344: 190-209.
20. García-Rill E. The pedunculopontine nucleus. Prog Neurobiol 1991; 36: 363-89.
21. Pahapill PA, Lozano A. The pedunculopontine nucleus and Parkinson's disease. Brain 2000; 123: 1767-83.
22. Obeso JA, Rodríguez-Oroz MC, Rodríguez M, Macías R, Álvarez L, Guridi J, et al. Pathophysiologic basis of surgery for Parkinson's disease. Neurology 2000; 55: 7-12.
23. DeLong M. Primate models of movement disorders of basal ganglia origin. TINS 1990; 13: 281-5.
24. Brundin P, Barbin G, Strecker R, Isacson O, Prochiantz A, Björklund A. Survival and function of dissociated rat dopamine neurons grafted at different developmental stages or after being cultured in vitro. Dev Brain Res 1988; 39: 233-43.
25. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. New York: Academic Press; 1986.
26. Ungerstedt U, Herrera-Marschitz M. Behavioural pharmacology of dopamine receptor mechanisms. In Starne L, Hedqvist P, Lagercrantz H, Wennmalm S, eds. Chemical neurotransmission, 75 years. New York: Academic Press; 1981. p. 481-94.
27. Zigmond M. Do compensatory processes underlie the preclinical phase of neurodegenerative disease? Insights from an animal model of Parkinsonism. Neurobiol Dis 1997; 4: 247-53.
28. Zadow B, Schmidt WJ. Lesions of the entopeduncular nucleus and the subthalamic nucleus reduce dopamine receptor antagonist-induced catalepsy in the rat. Behav Brain Res 1994; 62: 71-9.
29. Robinson TE, Camp DM. The feasibility of repeated microdialysis for within-subjects designs experiments: studies on the mesostriatal dopamine system. In Robinson TE, Justice JB, eds. Microdialysis in the Neurosciences. Amsterdam: Elsevier Sciences; 1991. p. 189-228.
30. Badiani A, Oates MM, Day HW, Watson SJ, Akil H, Robinson TE. Amphetamine-induced behavior, dopamine release, and c-fos mRNA expression: modulation by environmental novelty. J Neurosci 1998; 18: 10579-93.
31. Meshul CR, Emre N, Nakamura CM, Allen C, Donohue MK, Buckman JF. Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion. Neuroscience 1999; 88: 1-6.
32. Piallat B, Benazzouz A, Benabid AL. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioural and immunohistochemical studies. Eur J Neurosci 1996; 8: 1408-14.
33. Aziz TZ, Davies L, Stein J, France S. The role of descending basal ganglia connections to the brain stem in parkinsonian akinesia. J Neurosurg 1998; 12: 245-9.
34. Takada M, Matsumura M, Kojima J, Yamaji Y, Inase M, Tokuno H, et al. Protection against dopaminergic nigrostriatal cell death by excitatory input ablation. Eur J Neurosci 2000; 12: 1771-80.
35. García-Rill E, Skinner R. The mesencephalic locomotor region: activation of a medullary projection site. Brain Res 1987; 411: 1-12.
36. Breit S, Bouali-Benazzouz R, Denabid A, Benazzouz A. Unilateral lesion of the nigrostriatal pathway induces an increase of neuronal activity of the pedunculopontine nucleus, which is reversed by the lesion of the subthalamic nucleus in the rat. Eur J Neurosci 2001; 14: 1833-42.
37. Orieux G, Francois C, Féger J, Yelnik J, Vila M, Ruberg M, et al. Metabolic activity of excitatory parafascicular and pedunculopontine inputs to the subthalamic nucleus in a rat model of Parkinson's disease. Neuroscience 2000; 97: 79-88.
38. Nandi D, Aziz T, Giladi N, Winter J, Stein J. Reversal of akinesia in experimental Parkinsonism by GABA antagonists microinjections in the pedunculopontine nucleus. Brain 2002; 125: 2418-30.
39. Bevan MD, Bolam JP. Cholinergic, gabaergic and glutamate-enriched inputs from the mesopontine tegmentum to the subthalamic nucleus in the rat. J Neurosci 1995; 15: 7105-20.
40. Savasta M, Windels F, Bruet N, Bertrand A, Poupard A. Neurochemical modifications induced by high frequency stimulation of subthalamic nucleus in rats. In Nicholson L, ed. The basal ganglia VII. New York: Kluwer Academic Plenum Publisher; 2002. p. 581-90.
41. Futami T, Takakusaki K, Kitai S. Glutamatergic and cholinergic inputs from the pedunculopontine tegmental nucleus to dopamine neurons in the substantia nigra pars compacta. Neurosci Res 1995; 21: 331-42.
42. Kitai S, Shepard P, Callaway J, Scroggs R. Afferent modulation of dopamine neuron firing patterns. Curr Opin Neurobiol 1999; 9: 690-7.
43. Kojima J, Yamaji Y, Matsumura M, Nambu A, Inase M, Tokuno H, et al. Excitotoxic lesions of the pedunculopontine tegmental nucleus produce contralateral hemiparkinsonism in the monkey. Neurosci Lett 1997; 226: 111-4.
44. Dingledine R, McBain CHJ. Glutamate and aspartate. In Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD, eds. Basic neurochemistry. Molecular, cellular and medical aspects. Philadelphia: Lippincott Williams & Wilkins; 1999. p. 315-34.
45. Mitchell IJ, Clarke CE, Boyce S, Robertson R, Peggs D, Sambrook M. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl 4-phenyl-1,2,3,6- tetrahydropiridine. Neuroscience 1989; 32: 213-26.
46. Rodríguez M, Abdala P, Obeso JA. Excitatory responses in the 'direct' striatonigral pathway: effect of nigrostriatal lesion. Mov Disord 2000; 15: 795-803.
47. Smith Y, Kieval JZ Anatomy of the dopamine system in the basal ganglia. Trends Neurosci 2000; 23: 28-33.
48. Manaye KF, Zweing R, Wu D, Hersh LB, DeLacalle S, Saper CB, et al. Quantification of cholinergic and select non-cholinergic mesopontine neuronal populations in the human brain. Neuroscience 1999; 89: 759-70.
49. Scarnati E, Proia A, Di Loreto S, Pacitti C. The reciprocal electrophysiological influence between the nucleus tegmenti pedunculopontinus and the substantia nigra in normal and decorticated rats. Brain Res 1987; 423: 116-24.
50. Jackson EA, Kely PH. Role of nigral dopamine in amphetamine-induced locomotor activity. Brain Res 1983; 278: 366-9.
51. Penney JB, Difazio MC, Young AB. Glutamate binding sites in the substantia nigra of Parkinson's disease. Neurochem Int 1990; 16: 59-63.
52. Steiniger B, Kretchmer BD. Glutamate and GABA modulate dopamine in the pedunculopontine tegmental nucleus. Exp Brain Res 2003; 149: 422-30.